The emergence of influenza viruses with reduced susceptibility to baloxavir marboxil (BXM) would limit the clinical utility of this novel antiviral. To assess the risk of such resistance emerging, we evaluated influenza A and B viruses carrying BXM-reduced susceptibility substitutions and compared their fitness to that of their drug-susceptible […]
Q: What’s the difference between a cold and the flu, and how do you know which one you’ve got? Why can’t antibiotics help? A: Whether it’s a cold or the flu, the reason you are feeling awful is because you’ve been infected by a virus. More than 200 different […]
The PA-I38 mutations were noted frequently in influenza A/H3N2 viruses compared with A/H1N1pdm or influenza B viruses. The cap-dependent endonuclease inhibitor baloxavir marboxil was approved by the United States Food and Drug Administration in 2018 for the treatment of acute uncomplicated influenza in patients aged >12 years. 1 During […]
A research team has confirmed that mutated influenza viruses resistant to Xofluza, a widely used medication for respiratory flu, can cause infections and symptoms to a degree comparable to regular influenza viruses. | KYODO A research team has confirmed in animal testing that mutated influenza viruses resistant to baloxavir […]
RSVVW 2019 – A Global Conference on Novel RSV Preventive and Therapeutic Interventions.
RSV is a major cause of respiratory disease. This conference explored Novel RSV Preventive and Therapeutic Interventions, including antiviral, vaccines and monoclonal antibodies.
This was a global conference highlighting the challenge of the virus in LMICs
The conference was by all accounts a very successful and the organisers broadcast a free webinar on December 12th hosted by Prof. Louis Bont and Dr Natalie Mazur who gave a full summary of the highlights.
A replay of the webinar is available here and well worth a listen.
Further details of the conference itself are available here.
Slides from previous conferences on this cause of Respiratory Disease are here